Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial

Poveda, Andres M.; Selle, Frederic; Hilpert, Felix; Reuss, Alexander; Savarese, Antonella; Vergote, Ignace; Witteveen, Petronella; Bamias, Aristotelis; Scotto, Nana; Mitchell, Lada; Pujade-Lauraine, Eric

doi:https://doi.org/10.1200/JCO.2015.63.1408

Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial

DSpace/Manakin Repository

Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial

Poveda, Andres M.; Selle, Frederic; Hilpert, Felix; Reuss, Alexander; Savarese, Antonella; Vergote, Ignace; Witteveen, Petronella; Bamias, Aristotelis; Scotto, Nana; Mitchell, Lada; Pujade-Lauraine, Eric

(2015) Journal of Clinical Oncology, volume 33, issue 32, pp. 3836 - 3838

(Comment)

Download/Full Text

Open Access version via Utrecht University Repository

Publisher version

Version on publisher website for UU-students and staff

Version on publisher website

Keywords: Clinical Trial, Phase III, Letter, Randomized Controlled Trial, Research Support, Non-U.S. Gov't

DOI: https://doi.org/10.1200/JCO.2015.63.1408

ISSN: 0732-183X

Publisher: American Society of Clinical Oncology

(Peer reviewed)